Skip to main content
Top
Published in: Cancer Causes & Control 12/2010

Open Access 01-12-2010 | Original paper

Public policy action and CCC implementation: benefits and hurdles

Authors: Carter Steger, Kelley Daniel, Gary L. Gurian, J. T. Petherick, Chris Stockmyer, Annette M. David, Sara E. Miller

Published in: Cancer Causes & Control | Issue 12/2010

Login to get access

Abstract

Policy change continues to be an increasingly effective means of advancing the agenda of comprehensive cancer control. Efforts have moved progressively from describing how public policy can enhance the comprehensive cancer control agenda to implementation of public policy best practices at both the state and federal levels. The current political and economic contexts bring additional challenges and opportunities to the efforts surrounding comprehensive cancer control and policy. The purpose of this paper is to highlight recent policy successes, to illustrate the importance of policy as a means of advancing the comprehensive cancer control agenda, and to discuss continued policy action as we move forward in a time of healthcare reform and continuing economic uncertainty.
Literature
1.
go back to reference Selig KD et al (2005) Examining advocacy and comprehensive cancer control. Cancer Causes Control 16(Suppl 1):61–68CrossRefPubMed Selig KD et al (2005) Examining advocacy and comprehensive cancer control. Cancer Causes Control 16(Suppl 1):61–68CrossRefPubMed
3.
go back to reference Frieden TR (2010) A framework for public health action: the health impact pyramid. Am J Public Health 100:590–595CrossRefPubMed Frieden TR (2010) A framework for public health action: the health impact pyramid. Am J Public Health 100:590–595CrossRefPubMed
4.
go back to reference Townsend J (2010) Performance measures for NCCCP-funded programs: how CDC uses these data and how program directors can use these data. Presented at CDC’s NCCCP program director meeting, Los Angeles, CA, Hyatt Regency Century Plaza Townsend J (2010) Performance measures for NCCCP-funded programs: how CDC uses these data and how program directors can use these data. Presented at CDC’s NCCCP program director meeting, Los Angeles, CA, Hyatt Regency Century Plaza
5.
go back to reference American Cancer Society Cancer Action Network (2010) How do you measure up?: a progress report on State Legislative Activity to Reduce Cancer Incidence and Mortality, p 17 American Cancer Society Cancer Action Network (2010) How do you measure up?: a progress report on State Legislative Activity to Reduce Cancer Incidence and Mortality, p 17
6.
go back to reference Unpublished data gathered by the American Cancer Society Cancer Action Network in 2009 and 2010 Unpublished data gathered by the American Cancer Society Cancer Action Network in 2009 and 2010
7.
go back to reference American Cancer Society Cancer Action Network (2010) How do you measure up?: a progress report on State Legislative Activity to Reduce Cancer Incidence and Mortality, p 12 American Cancer Society Cancer Action Network (2010) How do you measure up?: a progress report on State Legislative Activity to Reduce Cancer Incidence and Mortality, p 12
8.
go back to reference American Cancer Society Cancer Action Network (2010) How do you measure up?: a progress report on State Legislative Activity to Reduce Cancer Incidence and Mortality, p 23 American Cancer Society Cancer Action Network (2010) How do you measure up?: a progress report on State Legislative Activity to Reduce Cancer Incidence and Mortality, p 23
12.
go back to reference Guam Cancer Facts and Figures 2003–2007. Department of Public Health and Social Services, Hagatna, Guam Guam Cancer Facts and Figures 2003–2007. Department of Public Health and Social Services, Hagatna, Guam
13.
go back to reference Guam State Epidemiological Workgroup (2009) Guam state epidemiological profile 2008 update. Department of Mental Health and Substance Abuse, Prevention and Training Branch, Hagatna, Guam Guam State Epidemiological Workgroup (2009) Guam state epidemiological profile 2008 update. Department of Mental Health and Substance Abuse, Prevention and Training Branch, Hagatna, Guam
14.
go back to reference Guam Comprehensive Cancer Control Coalition (2009) Guam cancer facts and figures 2003–2007. Department of Public Health and Social Services, Hagatna, Guam Guam Comprehensive Cancer Control Coalition (2009) Guam cancer facts and figures 2003–2007. Department of Public Health and Social Services, Hagatna, Guam
15.
go back to reference The World Bank (1999) Curbing the epidemic: governments and the economics of tobacco control. The World Bank, Washington The World Bank (1999) Curbing the epidemic: governments and the economics of tobacco control. The World Bank, Washington
16.
go back to reference World Health Organization Western Pacific Regional Office (2004) The establishment and use of dedicated taxes for health. World Health Organization, Manila World Health Organization Western Pacific Regional Office (2004) The establishment and use of dedicated taxes for health. World Health Organization, Manila
17.
go back to reference American Cancer Society (2010) Cancer facts and figures 2010, p 40 American Cancer Society (2010) Cancer facts and figures 2010, p 40
Metadata
Title
Public policy action and CCC implementation: benefits and hurdles
Authors
Carter Steger
Kelley Daniel
Gary L. Gurian
J. T. Petherick
Chris Stockmyer
Annette M. David
Sara E. Miller
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 12/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9668-5

Other articles of this Issue 12/2010

Cancer Causes & Control 12/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine